Laboratoires Servier signs licensing agreement with Cellectis for use of π10® modified cell lines in drug screening

CLS_PR_Servier_EN_090505.pdf

Neuilly-sur-Seine and Parc Biocitech, Romainville, May 5, 2009 – the genome engineering company Cellectis S.A. (Alternext: ALCLS) and the pharmaceutical group Servier today announced the signature of a non-exclusive licensing agreement for the use of Cellectis’ π10® modified cell lines for high-throughput screening. The license concludes a fruitful period of research under the terms of a 2007 collaboration agreement between the two companies.

Bernard Marchand, Servier’s Head of Research, said: “This agreement formalizes a well-established research relationship with Cellectis and will accelerate the development of high-performance screening tools for innovative drug targets.”

“The licensing agreement with Servier crowns a particularly effective partnership between the two companies’ research divisions. The cells, gene insertion templates and meganuclease used by Servier are now available as a commercial kit which provides a reliable, easy-to-use method of creating cell lines specific to drug targets of interest,” commented Marc Le Bozec, Cellectis’ Chief Financial Officer and CEO of Cellectis BioResearch, the subsidiary responsible for marketing research kits.